The Oncology Institute, Inc. (TOI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with increased pharmacy revenue and improved gross margins. The Q&A section reveals positive insights on drug pricing reforms and growth in patient lives, despite some vague responses from management. Overall, the company's strategic initiatives and financial metrics suggest a positive outlook, likely boosting the stock price by 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Second quarter revenue of $120 million, representing a year-over-year growth of more than 20%. This growth was driven by monthly records in the pharmacy business and 10% year-over-year growth in the fee-for-service business, particularly in Florida and Oregon.
Adjusted EBITDA Adjusted EBITDA loss of $4.1 million in Q2, which is a $4.6 million improvement compared to the same quarter last year. This reduction in loss was primarily due to organic fee-for-service and pharmacy revenue growth, disciplined clinical payroll and SG&A management, and improved drug margins.
Pharmacy Revenue Pharmacy revenue of $62.6 million in Q2, a 41% increase compared to Q2 of last year and a 27% sequential increase. This growth was driven by increased patient volumes, reduced prescription leakage, and operational discipline.
Gross Profit Gross profit of $17.5 million in Q2, a 34% year-over-year increase. Gross margin improved by 140 basis points year-over-year to 14.6%, driven by better dispensary gross margins, though partially offset by a slight decline in patient services gross margin.
SG&A Expenses SG&A expenses of $26.9 million in Q2, a 3.5% decrease from the same period last year. Normalizing for a $2.4 million one-time write-off, SG&A would have decreased 12% year-over-year, reflecting operational leverage and cost discipline.
Cash Flow Cash flow from operations for the first half of 2025 was a loss of $15.2 million, a 52% improvement from the first half of 2024. Free cash flow was negative $14.6 million for the first 6 months, a 54.1% reduction from the same period last year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pharmacy Business Growth: Achieved over 40% growth in Q2 2025 compared to Q2 2024, driven by increased patient volumes and reduced prescription leakage. Forecasting over 35% growth for the full year.
AI Enablement Initiatives: Launching three AI initiatives in Q3 2025 to improve revenue cycle management, prior authorization services, and patient call center operations.
Capitated Contracts Expansion: Added over 50,000 capitated lives in Nevada and California in Q2 2025. Expanded capitation relationship with Silver Summit Health Plan in Nevada, adding 49,000 Medicaid patient lives. Reached a verbal agreement to expand a partnership in Florida, adding over 40,000 Medicare Advantage lives in Q4 2025.
Geographic Expansion: Focused on expanding capitated relationships and partnerships in nearly every market where TOI operates.
Revenue Growth: Achieved 21.5% year-over-year revenue growth in Q2 2025, reaching $119.8 million. Pharmacy revenue grew 41%, and patient services revenue grew 7%.
Cost Management: Reduced SG&A expenses by 12% year-over-year, representing 22% of total revenue in Q2 2025. Improved drug margins through strategic purchasing and formulary management.
Leadership Changes: Appointed Kristin England as Chief Administrative Officer to oversee business operations and technology strategy. Anne McGeorge elected as new Chair of the Board.
Technology and AI Strategy: Focused on transforming into a technology and AI-enabled care delivery organization to improve patient and physician experience while reducing operational expenses.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Compliance Risks: The company acknowledges risks and uncertainties related to forward-looking statements and guidance, which could cause actual results to differ materially. This includes potential regulatory hurdles and compliance challenges.
Financial Performance Risks: Despite improvements, the company reported an adjusted EBITDA loss of $4.1 million in Q2 2025. Achieving positive adjusted EBITDA by Q4 remains a challenge, with risks tied to revenue growth, cost management, and operational efficiencies.
Capitation Contract Risks: New capitation contracts tend to experience lower margins initially as the company works to operationalize and mature these contracts. This could impact short-term profitability.
Pharmacy Business Risks: The company is heavily reliant on its pharmacy business, which experienced significant growth. However, this growth increases accounts receivable and rebate AR, creating cash flow management challenges.
Supply Chain and Drug Cost Risks: Rising drug costs and reliance on strategic purchasing and formulary management pose risks. Delays in rebate payments from manufacturers could also impact cash flow.
Operational and Technological Risks: The company is launching AI enablement efforts to improve cost efficiency and operational performance. However, the success of these initiatives is uncertain and could impact operational outcomes.
Leadership Transition Risks: The retirement of the current Chairman and the appointment of a new Chair could create transitional challenges and impact strategic decision-making.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects full-year 2025 revenue to be in the range of $460 million to $480 million, with a strong belief in reaching the high end of this range due to growth in the first half of the year.
Adjusted EBITDA: The company anticipates adjusted EBITDA for 2025 to range from a loss of $17 million to a loss of $8 million, with a solid line of sight to the midpoint of this range. Positive adjusted EBITDA is expected in Q4 2025.
Pharmacy Business Growth: The pharmacy business is forecasted to grow over 35% for the full year compared to the prior year, driven by increased patient volumes and reduced prescription leakage. An additional pharmacy location in Florida is expected to open in the second half of 2025.
Capitated Partnerships: The company plans to expand capitated partnerships, including a new contract in Florida starting in Q4 2025, which will add over 40,000 Medicare Advantage lives. This expansion will double the current relationship with the payer and bring total Medicare Advantage lives under capitation in Florida to over 100,000.
Gross Margin Improvement: Sequential improvement in gross margin is anticipated in the second half of 2025, driven by optimization of risk margins, drug pricing spread expansion, and supply chain and formulary management.
AI Enablement: The company is launching three AI initiatives in Q3 2025 to improve performance and reduce costs in revenue cycle management, prior authorization services, and the patient call center.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the dispensing gross margin and what is driving the year-over-year increase?
A:The increase in dispensing gross margin is attributed to the worst impact from the EARP clawback in Q2 of last year, which made the margin artificially low. Even after normalization, there is double-digit growth year-over-year due to improved drug procurement, scale providing new opportunities, incremental rebates, and better pricing considerations.
Q:Are the medications discussed Part B or Part D?
A:The medications discussed are Part D medications, primarily oral specialty or self-injectables that can be compliantly given under Part D.
Q:What is the potential impact of drug pricing reform, including the Inflation Reduction Act, on your business?
A:The drug pricing reform is expected to be net positive for TOI. Reduction in pricing benefits capitated margins and patients, while fee-for-service practices may receive rebates or other mechanisms to stay afloat. These factors combined are favorable for TOI.
Q:Are there any specific drugs in your portfolio that could significantly impact your business due to pricing changes?
A:No, there are no single drugs in TOI's portfolio that pose substantial risk due to pricing changes. Oncology benefits from multiple clinically equivalent options within any given class, including biosimilars.
Q:Can you elaborate on the pressure on the gross patient service margin and the timeline for improvement?
A:The pressure is primarily related to the cap margin due to a sizable contract launch in March in the Florida oncology network. Patients are still in the continuity of care period, and margins are expected to improve over the next three months as patients transfer to TOI clinics.
Q:What are your observations on oncology spending trends in 2Q 2025, and can you manage costs at a low level in the second half of 2025?
A:Oncology spending trends showed huge increases in drug cost trends, driven by lower utilization and increased procurement costs. TOI has managed to keep its MLR stable through network narrowing, UM program control, and value-based therapeutic decision-making. Drug cost trends for TOI have been stable.
Q:Can you comment on the timeline for the opportunity in Florida and revenue recognition?
A:The opportunity in Florida is tracking towards Q4, and revenue recognition will start in Q4.
Q:Have you noticed PBMs shifting infusion drugs from clinic to their own pharmacy, and will it negatively impact you?
A:TOI's risk contracts are almost exclusively Part B risk only. Shifting drugs from Part B to Part D would remove costs at risk to TOI, which would be net positive.
Q:Can you provide details about new patients from contracts and the growth in patient lives?
A:Growth in the second half of 2025 is primarily outside California, with higher utilization and PMPM rates. Florida is projected to have around 100,000 Medicare Advantage lives by year-end, doubling from the current 50,000. This represents an incremental 2.5% growth in TOI's total portfolio of 1.9 million lives.
Q:What does 'fully delegated risk arrangements' mean, and what responsibilities does TOI have?
A:'Fully delegated risk arrangements' mean TOI takes risk for Part B oncology spend and is delegated authority for utilization management, network design, and claims adjudication. This allows TOI to manage oncology spend across broader populations and provide value-based care at scale.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about the specific timeline for patient transfer to TOI clinics and the exact impact of PBM shifts on TOI's business. Their responses lacked precise data and were somewhat vague.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI enablement
AR
Chair
Chief Financial
Corporate Participant
Financial Officer
Florida Oregon
Inc Research
MSO practice
Nevada California
Research Division
SGA
TOI model
executive
experience
increase fee
investment
leverage
manufacturer
margin basis
margin capitation
medication
partnership
pharmacy discipline
pharmacy fee
proposition TOI
rebate
reduction
relationship
reminder
service Florida
service increase
value TOI
volume drug
TOI Transcript
The Oncology Institute, Inc. (TOI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call demonstrates strong financial performance with improved MLR and profitability in Florida, positive growth in dispensary attachment rates, and significant free cash flow improvements. The Q&A reveals optimism about expanding health plan agreements and leveraging pharmacy networks. Although management was vague about specific health plans, the overall sentiment remains positive due to the company’s strategic growth and profitability in key markets. Despite the lack of market cap data, the positive financial and strategic developments suggest a likely stock price increase.
The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript
Positive3-13
The earnings call summary indicates a positive financial performance with increased revenue, adjusted EBITDA, and free cash flow. The company has raised its revenue and EBITDA guidance for 2025, suggesting confidence in future performance. Although there are risks and uncertainties highlighted, the overall outlook remains positive with expected profitability and cash flow positivity. The strategic initiatives, including AI enablement, are likely to drive future efficiencies. Despite the absence of a market cap, the positive financial metrics and guidance suggest a stock price increase in the 2% to 8% range.
The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.
The Oncology Institute, Inc. (TOI) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights strong financial performance with increased pharmacy revenue and improved gross margins. The Q&A section reveals positive insights on drug pricing reforms and growth in patient lives, despite some vague responses from management. Overall, the company's strategic initiatives and financial metrics suggest a positive outlook, likely boosting the stock price by 2% to 8% over the next two weeks.
TOI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
